RecruitingPHASE1, PHASE2NCT06898450
A Study to Assess the Safety, Tolerability, and Efficacy of NDI-219216 in Patients With Advanced Solid Tumors.
Studying Hereditary nonpolyposis colon cancer
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Nimbus Wadjet, Inc.
- Principal Investigator
- Anita Scheuber, MD, PhDNimbus Therapeutics, Inc.
- Intervention
- NDI-219216(drug)
- Enrollment
- 134 enrolled
- Eligibility
- 18-99 years · All sexes
- Timeline
- 2025 – 2031
Study locations (29)
- USC Norris Comprehensive Cancer Center, Los Angeles, California, United States
- University of Chicago Medicine, Chicago, Illinois, United States
- University of Louisville James Graham Brown Cancer Center, Louisville, Kentucky, United States
- Cayuga Cancer Center, Ithaca, New York, United States
- Levine Cancer Center, Charlotte, North Carolina, United States
- Atrium Health Wake Forest Baptist Center, Winston-Salem, North Carolina, United States
- Taylor Cancer Research Center, Maumee, Ohio, United States
- Brown University Health, Providence, Rhode Island, United States
- Prisma Health Cancer Institute - Multidisciplinary Center, Greenville, South Carolina, United States
- University of Virginia Emily Couric Clinical Cancer Center, Charlottesville, Virginia, United States
- Virginia Cancer Specialists, P.C. - Fairfax, Fairfax, Virginia, United States
- Liverpool Hospital, Liverpool, New South Wales, Australia
- Southern Oncology Clinical Research Unit, Bedford Park, South Australia, Australia
- BC Cancer Center, Kelowna, British Columbia, Canada
- Princess Margaret Cancer Center, Toronto, Ontario, Canada
- +14 more locations on ClinicalTrials.gov
Collaborators
Worldwide Clinical Trials
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT06898450 on ClinicalTrials.govOther trials for Hereditary nonpolyposis colon cancer
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE1NCT07163403First in Human Pilot Study to Assess the Safety and Efficacy of Dendritic Cells Loaded With Frameshift Derived Neopeptides for the Prevention of Cancer in of Lynch Syndrome CarriersFundacion Clinic per a la Recerca Biomédica
- RECRUITINGNANCT05963191CAD-EYE System for the Detection of Neoplastic Lesions in Patients With Lynch SyndromePERROD Guillaume
- RECRUITINGNCT06708429Lynch Syndrome X-Talk of Enteral Mucosa With Immune SystemSan Raffaele University
- ACTIVE NOT RECRUITINGPHASE2NCT05419011Testing a Combination of Vaccines for Cancer Prevention in Lynch SyndromeNational Cancer Institute (NCI)
- RECRUITINGNANCT07219537A Study for Imaging the Lower Gastrointestinal Tract Using a Retro-TCE CapsuleMassachusetts General Hospital
- ACTIVE NOT RECRUITINGPHASE1NCT05078866Cancer Preventive Vaccine Nous-209 for Lynch Syndrome PatientsNational Cancer Institute (NCI)
- ACTIVE NOT RECRUITINGPHASE3NCT02813824Effect of Chemoprevention by Low-dose Aspirin of New or Recurrent Colorectal Adenomas in Patients With Lynch SyndromeAssistance Publique - Hôpitaux de Paris
- ACTIVE NOT RECRUITINGNCT02371135Metagenomic Evaluation of the Gut Microbiome in Patients With Lynch Syndrome and Other Hereditary Colonic Polyposis SyndromesMemorial Sloan Kettering Cancer Center